title: CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome.
abstract: Effects of the CCK(B) antagonists, CAM1028 and C1988, and the CCK(A) antagonist, CAM1481, were studied on the ethanol withdrawal syndrome. When handling-induced behavior was measured hourly for 12 h from withdrawal of ethanol, a small, but significant, protective effect was seen with 3 mg/kg CAM1028, but not with 0.3, 1, or 10 mg/kg. C1988 (0.3 1,3, or 10 mg/kg), or CAM1481 (0.1 or 1 mg/kg), had no effects. At 16 h from ethanol withdrawal, these ratings were significantly decreased by 3 mg/kg CAM1028 or C1988, but not by lower doses. At 16 h, CAM1481 had very small, but significant, protective effects. At 3 mg/kg, CAM1028, increased the latencies to audiogenic seizures, but had only small effects on convulsion incidence. CAM1481 did not alter the audiogenic convulsions. The decrease in convulsion thresholds to NMDLA, at 16 h from ethanol withdrawal, was completely prevented by CAM1028 or C1988, at 1 and at 3 mg/kg, but not by lower doses; CAM1481 had no significant effects. The results suggest change in CCK(B) receptors may be involved in the later stages of the ethanol withdrawal syndrome.
authors.affiliation: Department of Pharmacology, School of Medical Sciences, Bristol, UK.
authors.forename: J
authors.initials: J
authors.lastname: Wilson
authors.forename: H J
authors.initials: HJ
authors.lastname: Little
mesh_terms: D000161:Acoustic Stimulation; D000437:Alcoholism / Q000503:physiopathology / Q000523:psychology; D000818:Animals; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001522:Behavior, Animal / Q000187:drug effects; D002492:Central Nervous System Depressants / Q000009:adverse effects*; D004151:Dipeptides / Q000627:therapeutic use*; D000431:Ethanol / Q000009:adverse effects*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D006234:Handling, Psychological; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008536:Meglumine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008815:Mice, Inbred Strains; D016202:N-Methylaspartate / Q000494:pharmacology; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors*; D012640:Seizures / Q000503:physiopathology; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy* / Q000523:psychology
chemical_list: D014151:Anti-Anxiety Agents; C097931:CAM 1481; D002492:Central Nervous System Depressants; D004151:Dipeptides; D018690:Excitatory Amino Acid Agonists; D007211:Indoles; D011949:Receptors, Cholecystokinin; C065600:PD 135158; C065599:PD 134308; D000431:Ethanol; D016202:N-Methylaspartate; D008536:Meglumine